$INGN

Inogen (NASDAQ:INGN) reported Q2 results with improving profitability and continued international growth, but weakness in the US oxygen rental and direct-to-consumer channels. International revenue was $41.3M (+15% YoY). US sales fell 2% to $42.3M and rental revenue dropped 12% to $11.6M. Full-year 2026 revenue guidance was cut to $355M-$361M.

Inogen (INGN) reported Q2 2026 revenue of $95.1 million, up 3% year over year, driven by international sales of $41.3 million (+14.8%) and new product contributions. U.S. sales were $42.3 million, down 2.3%. Adjusted EBITDA was $2.4 million (+15.2%). Full-year revenue guidance was cut to $355-$361 million; adjusted EBITDA guidance is about $4 million. Cash was $106.8 million with zero debt.

Inogen (INGN) cut its 2026 revenue outlook to $355 million to $361 million from $366 million to $373 million after Q2 results showed ongoing U.S. channel pressure. Q2 U.S. sales fell 2.3% to $42.3M and U.S. rentals fell 11.8% to $11.6M, while international revenue rose 14.8% to $41.3M. Adjusted gross margin rose to 45.6%.

Inogen Inc (INGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inogen Announces Second Quarter 2026 Financial Results Reported second quarter revenue of $95.1 million Company raises full-year adjusted EBITDA guidance to approximately $4.0 million BEVERLY, Mass., August 6, 2026 -- Inogen, Inc. (Nasdaq: INGN ), a medical technolog

Inogen Inc (INGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ingn-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 INOGEN, INC. EMPLOYMENT AND SEVERANCE AGREEMENT This Employment and Severance Agreement (this “ Agreement ”) is made and effective on or before a start date of July 6, 2026 (the “ Effective Date ”), by and between Inogen, Inc

Inogen Inc (INGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ingn-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 INOGEN, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN 1. Purposes of the Plan . The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to prov

Inogen Inc. (INGN) reported mixed Q1 2026 results, with revenue of $85.1 million ahead of forecasts by 3.34% due to strong international sales growth, while EPS missed predictions at -$0.30 against -$0.29. Despite the EPS miss, the stock saw a modest 0.7% increase in aftermarket trading, reflecting cautious optimism driven by the revenue beat and strategic product launches like the Aurora CPAP mask. The company reaffirms its 2026 revenue guidance, expecting stronger profitability in Q2 and Q3 due to seasonal trends and continued investment in new markets and product innovation.

Inogen Inc's VP and Chief Accounting Officer, Mary E. Wright, reported several equity compensation transactions detailed in a recent Form 4 SEC filing. These included the exercise or conversion of restricted stock units into common stock, grants of common stock, and shares withheld for tax liabilities. A new grant of 8,000 restricted stock units was also awarded, vesting over several years.

Inogen Inc.'s CEO, Kevin Raymond Merrill Smith, received a grant of 90,000 restricted stock units (RSUs) on February 27, 2026, which will vest over three years. He also had performance-based and time-based RSUs vest on March 1, 2026, leading to share acquisitions and subsequent share withholdings to cover tax liabilities. This information was reported in a recent SEC Form 4 filing.

Inogen (INGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.